logo

For the Inventor, By the Inventor

Lehi, UT, United States of America

Tolero Pharmaceuticals, Inc.


USPTO Granted Patents = 21

% Expired Patents = 9.5


Forward Citations = 194

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal David J Bearss (13 out of 50 patents)

silverMedal Steven L Warner (11 out of 36 patents)

bronzeMedal Adam Siddiqui-Jain (8 out of 25 patents)

4.  Yong Xu (7 out of 37 patents)

5.  Xiaohui Liu (6 out of 11 patents)

6.  Michael David Saunders (6 out of 9 patents)

7.  Koc-Kan Ho (6 out of 50 patents)

8.  Clifford J Whatcott (5 out of 9 patents)

9.  Jason Marc Foulks (3 out of 7 patents)

10.  Jihua Liu (3 out of 11 patents)

11.  Kenneth Mark Parnell (3 out of 11 patents)

12.  Benjamin Gary Brenning (3 out of 4 patents)

13.  Steven G Kultgen (3 out of 9 patents)

14.  Scott Albert Pearce (3 out of 4 patents)

15.  Kevin Bret Wright (3 out of 5 patents)


21 patents:

1. 10682356 - Combination therapies for treatment of cancer (2020-06-16),
2. 10624880 - Predicting response to alvocidib by mitochondrial profiling (2020-04-21),
3. 10568887 - Combination therapies for treatment of cancer (2020-02-25),
4. 10562925 - Alvocidib prodrugs having increased bioavailability (2020-02-18),
5. 10472328 - PKM2 modulators and methods for their use (2019-11-12),
6. 10422788 - Profiling peptides and methods for sensitivity profiling (2019-09-24),
7. 10392392 - Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2019-08-27),
8. 10357488 - Predicting response to alvocidib by mitochondrial profiling (2019-07-23),
9. 10267787 - Profiling peptides and methods for sensitivity profiling (2019-04-23),
10. 10259835 - Alvocidib prodrugs having increased bioavailability (2019-04-16),
11. 10207996 - PKM2 modulators and methods for their use (2019-02-19),
12. 10202356 - JAK2 and ALK2 inhibitors and methods for their use (2019-02-12),
13. 10132797 - Profiling peptides and methods for sensitivity profiling (2018-11-20),
14. 10047093 - Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2018-08-14),
15. 9901574 - Predicting response to alvocidib by mitochondrial profiling (2018-02-27),
Company Overview
Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Lehi, Utah, focused on developing innovative therapies for patients with cancer and other serious diseases. The company specializes in advancing novel drug candidates that target specific molecular pathways, aiming to improve treatment outcomes and quality of life for patients. Tolero's research emphasizes precision medicine, leveraging scientific insights to create tailored therapeutic solutions that address unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Tolero Pharmaceuticals, Inc. USPTO Patent Assignee Logo
21 Patents

#10 in Lehi, UT

#179 in Utah

#15,695 in US

#29,961 in the World

Lehi, UT (US)
Lehi, UT, United States of America

Tolero Pharmaceuticals, Inc.

Forward Citations = 194

26 inventors:

goldMedal David J Bearss (13 out of 50 patents)

silverMedal Steven L Warner (11 out of 36 patents)

bronzeMedal Adam Siddiqui-Jain (8 out of 25 patents)

4.  Yong Xu (7 out of 37 patents)

5.  Xiaohui Liu (6 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tolero Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/tolero-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…